Nonlymphomatous malignant tumors complicating Hodgkin's disease. Possible association with intensive therapy.
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects; D002294:Carcinoma, Squamous Cell / Q000209:etiology; D003520:Cyclophosphamide / Q000627:therapeutic use; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D005354:Fibrosarcoma / Q000209:etiology; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000209:etiology; D006689:Hodgkin Disease / Q000150:complications* / Q000188:drug therapy / Q000532:radiotherapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000139:chemically induced*; D009381:Neoplasms, Radiation-Induced / Q000209:etiology*; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011344:Procarbazine / Q000627:therapeutic use; D011878:Radiotherapy / Q000009:adverse effects; D012075:Remission, Spontaneous; D013997:Time Factors; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D009588:Nitrogen Mustard Compounds; D011344:Procarbazine; D014750:Vincristine; D003520:Cyclophosphamide; D011241:Prednisone